Washington Growth Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Washington Growth Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$496K	Hold	998	–	–	0.28%	45
2026 Q1	$446K	Hold	998	–	–	0.29%	46
2025 Q4	$452K	Hold	998	–	–	0.29%	43
2025 Q3	$391K	Hold	998	–	–	0.28%	43
2025 Q2	$444K	Buy	998 +513	+106%	+$236K	0.34%	39
2025 Q1	$205	Buy	+485	New	+$226K	0.18%	42
2024 Q3	$423	Buy	+193	New	+$92.7K	0.02%	65

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Washington Growth Strategies's VRTX Position: Q2 2026 in Review

Washington Growth Strategies held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 998 shares worth $496K. The position accounts for 0.28% of the portfolio, ranked #45.

Washington Growth Strategies first reported a position in VRTX in Q3 2024 and has held it in 7 quarters since. 389 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Washington Growth Strategies held 998 shares of Vertex Pharmaceuticals worth $496K as of Q2 2026.
Washington Growth Strategies left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.28% of Washington Growth Strategies's portfolio in Q2 2026, its #45 holding.
Washington Growth Strategies first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
389 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Washington Growth Strategies's 13F filing for Q2 2026, filed 16 Jul 2026.